Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01502293 · ClinicalTrials.gov registry record · Phase 2
Trial of pIL-12 Electroporation Malignant Melanoma
A Phase 2 study of Melanoma, sponsored by OncoSec Medical Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 6
- Study locations
NCT01502293 is a Phase 2 study of Melanoma that has completed, run by OncoSec Medical Incorporated. The registered enrollment target is 51 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (93% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT01502293, a Phase 2 study of Melanoma, has completed, sponsored by OncoSec Medical Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study will assess the safety and effectiveness of different dosing regimens of ImmunoPulse IL-12® in malignant melanoma. ImmunoPulse IL-12® is the combination of intratumoral interleukin-12 gene (also known as tavokinogene telseplasmid \[tavo\]) and in vivo electroporation-mediated plasmid deoxyribonucleic acid \[DNA\] vaccine therapy (tavo-EP) administered using the OncoSec Medical System (OMS). ImmunoPulse IL-12® is a gene therapy approach to directly induce a pro-inflammatory response within a tumor to initiate and/or enhance anti-tumor immunity.
Conditions Studied
Interventions
- BIOLOGICAL Tavokinogene Telseplasmid (tavo)
- DEVICE OncoSec Medical System (OMS)
Study Locations (6)
California
- UCSF Helen Diller Comprehensive Cancer Center - San Francisco
- John Wayne Cancer Institute - Santa Monica
Colorado
- University of Colorado Denver - Denver
Florida
- Lakeland Regional Cancer Center - Lakeland
Pennsylvania
- St. Luke's University Health Network - Bethlehem
Washington
- Seattle Cancer Care Alliance /University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2012-02-14 |
| Est. Completion | 2016-03-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01502293
The ClinicalTrials.gov registry entry for NCT01502293 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (93% lower). The listed sponsor is OncoSec Medical Incorporated, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Tavokinogene Telseplasmid (tavo) is the first listed.
NCT01502293 reports 6 study locations spanning 5 distinct geographic areas - top geographies include California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT01502293 about?
NCT01502293 is a clinical study titled "Trial of pIL-12 Electroporation Malignant Melanoma". This study will assess the safety and effectiveness of different dosing regimens of ImmunoPulse IL-12® in malignant melanoma. ImmunoPulse IL-12® is the combination of intratumoral interleukin-12 gene (also known as tavokinogene telseplasmid \[tavo\]) and in vivo electroporation-mediated plasmid deox...
What is the current status of trial NCT01502293?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2012-02-14. Estimated completion is 2016-03-21.
What conditions does trial NCT01502293 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT01502293?
The interventions under investigation include: Tavokinogene Telseplasmid (tavo) (BIOLOGICAL), OncoSec Medical System (OMS) (DEVICE).
Who is sponsoring clinical trial NCT01502293?
This trial is sponsored by OncoSec Medical Incorporated, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01502293 being conducted?
This trial has 6 study locations across California, Colorado, Florida, Pennsylvania, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.